Newsletter

The cost of employer-sponsored health benefits will rise 6.5% in the U.S. in 2020, or about 3.8 percentage points higher than the overall inflation rate, according to a report by consulting firm Aon...

Democratic presidential candidates held their third debate Thursday night, and once again a sizable portion of the debate — 21%, according to a Bloomberg analysis — was devoted to health care policy...

In a The New York Times op-ed, Ezekiel Emanuel, a health policy expert and a former adviser in the Obama administration, and Victor Fuchs, a Stanford health economist, look to clarify what they call...

If you watch tonight’s Democratic debates, you’re likely going to see some attacks on Medicare for All and the idea of a public option that would allow anyone to buy into a Medicare-style plan. Those...

Whether Congress will act this year to address the affordability of prescription drugs — a high priority among voters — remains uncertain. But states aren’t waiting. So far this year, 33 states have...

High levels of government debt spur governments to rein in health care costs, according to a new report from economists at Goldman Sachs. And efforts to reduce health care inflation may help explain...

The pharmaceutical industry has hit a new low in the eyes of the American public: It is now the most poorly regarded industry in the country, according to a new Gallup survey. Americans are more than...

Drug companies are starting to be held accountable for the opioid crisis they helped create, with Purdue Pharma, which makes OxyContin, reportedly offering to pay $10 billion to $12 billion to settle...